Dealing with cancer screening in the COVID-19 era
Rev. Assoc. Med. Bras. (1992); 67 (supl.1), 2021
Publication year: 2021
SUMMARY OBJECTIVE:
This article aims to alert health professionals for cancer screening in the face of the possibility of new waves of disease.METHODS:
A narrative review was conducted through a search in MEDLINE, Lilacs, Chinese Biomedical Literature Database, and international medical societies publications.RESULTS:
Breast cancer: in high-risk patients (confirmed familial cancer syndrome or with high-risk tools scores), clinicians should act according to usual recommendations; in average-risk individuals, consider screening with mammography with a longer time span (maximum of two years).Cervical cancer:
women turning 25 years old who have already been immunized and with no previous Pap test can have the test postponed during the pandemic; if there is no previous dose of Human Papillomavirus vaccination, initiation of screening should be recommended following a more rigid approach for COVID prevention; in women over 30 years of age who have never participated in cervical screening, the first screening exam is also essential.Colorectal cancer:
if the individual is at elevated risk for familial cancer, the screening with colonoscopy according to usual recommendations should be supported; if at average risk consider screening with Fecal Occult Blood Test.Prostate cancer:
there is a trend to postpone routine prostate cancer screening until the pandemic subsides.CONCLUSIONS:
The decision to keep cancer screening must be discussed and individualized, considering the possibility of new waves of COVID-19.
COVID-19, Neoplasias Colorrectales, Detección Precoz del Cáncer, Tamizaje Masivo, Infecciones por Papillomavirus, Vacunas contra Papillomavirus, Antígeno Prostático Específico, Neoplasias de la Próstata, SARS-CoV-2, Neoplasias del Cuello Uterino/diagnóstico, Neoplasias del Cuello Uterino/prevención & control